Marina Biotech Signs Definitive Agreement with Windlas

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
60
Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet

CITY OF INDUSTRY, CA--(Marketwired - Apr 3, 2017) - Marina Biotech, Inc. ( OTCQB : MRNA ), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it has signed a definitive agreement with Windlas Healthcare Limited for the manufacture of its IT-102 fixed-dose combination (FDC) bi-layer tablets.

"This agreement marks the culmination of an in-depth due diligence and qualification process, during which we evaluated dozens of manufacturers, and Windlas came out ahead," stated Joseph Ramelli, CEO of Marina Biotech. "The manufacturing of the FDC bi-layer tablets requires additional equipment and expertise that Windlas possesses. Now with this agreement in place we are positioned to move into a pivotal phase 3 clinical study by the first quarter of 2018."

Marina Biotech's IT-102, a celecoxib and lisinorpril FDC, is being developed for the combined treatment of arthritis and hypertension. The preference for and improved compliance with a single tablet makes the proposed FDC formulation a very useful drug for treatment of 2 common conditions with increasing frequency in the aging population. Additionally, the combination of lisinopril with celecoxib may reduce the incidence of cardiovascular adverse events and edema associated with celecoxib treatment, potentially making it a preferred treatment for pain. IT-102 will be further developed for treatment of familial adenomatous polyposis (FAP).

Windlass Healthcare Limited (WHC) corporate headquarters is in Gurgaon, India. The company was established in 2008 in Dehradun, and the manufacturing facilities are designed as per the US Food and Drug Administration (US FDA), and European Union current Good Manufacturing Practices (EU cGMP) standards. The manufacturing plant has received approval from USFDA.

About Marina Biotech Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 - next generation celecoxib -- which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com .

Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to successfully integrate its business operations with those of IthenaPharma; (ii) the ability of Marina Biotech to obtain funding to support its clinical development; (iii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iv) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (v) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (vi) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

Investor Contact Garth Russell / Allison Soss KCSA Strategic Communications Phone: (212) 896-1250 / (212) 896-1267 Email: Email Contact / Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 82

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 5

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 131

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 96

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 253

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 18

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 176

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Lawsuit: CarMax Investors, Time to Act Now!

Updated Category News Views 232

Class Action Lawsuit for CarMax Investors Investors in CarMax, Inc. (NYSE: KMX) have found themselves facing a significant legal opportunity. The Rosen Law Firm, noted for its focus on protecting investor rights, has initiated a class action lawsuit that specifically addresses the concerns of securitiesholders. This lawsuit applies to purchasers of CarMax securities from...

Continue Reading
Plumbing Pitfalls: When Water Heater Noises Spell Trouble

Updated Category News Views 33

Understanding the Clamor from Your Water Heater The hustle and bustle of everyday life often drown out the less important noises. But when your water heater starts making a ruckus, maybe it's time to listen. From the keen ears of Jared Voss, a plumbing expert with his roots dug deep in Clinton, Iowa, we get the lowdown on what these noises could mean for your plumbing....

Continue Reading
Walmart Enhances Shopping Experience with Inclusive Carts

Updated Category News Views 288

Walmart Launches Caroline's Carts to Enhance Shopping Experience Today, Walmart is taking a big step toward inclusivity by introducing Caroline’s Carts in its stores across Tennessee. These specially designed shopping carts aim to assist caregivers who look after both children and adults with disabilities, making the shopping experience easier for everyone involved....

Continue Reading
Innovative Cancer Treatments by Cyncado Enhance Tumor Regression

Updated Category News Views 191

Introduction to Promising Cancer Treatment Strategies AlphaTON Capital Corp (NASDAQ: ATON) is making significant strides through its subsidiary Cyncado Therapeutics, particularly in the realm of oncology. Recently, they unveiled their latest preclinical studies focusing on the dynamic interaction between selective A2B and A2A receptor antagonists and cancer vaccines....

Continue Reading
Vertex Stock Insights: Recent Insider Trading Highlights

Updated Category News Views 42

Significant Trading Activity at Vertex Inc. Recently, it was made known that ITEM SECOND IRR TRUST FBO ANNE MARIE WESTPHAL, a 10% owner at Vertex (NASDAQ: VERX), executed a notable insider transaction. This insider sell, documented through an SEC filing, included 75,175 shares, accumulating a transaction value of approximately $3,018,885. As the market opened the...

Continue Reading